Debra L. Weiner, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 9 | 2023 | 1065 | 0.740 |
Why?
|
| Pediatrics | 7 | 2020 | 3629 | 0.480 |
Why?
|
| Disasters | 2 | 2011 | 521 | 0.410 |
Why?
|
| Benzocaine | 1 | 2011 | 14 | 0.390 |
Why?
|
| Disaster Planning | 3 | 2014 | 559 | 0.310 |
Why?
|
| Rescue Work | 1 | 2006 | 58 | 0.260 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2004 | 25 | 0.240 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2004 | 329 | 0.210 |
Why?
|
| Antisickling Agents | 1 | 2003 | 72 | 0.210 |
Why?
|
| Disaster Medicine | 1 | 2024 | 75 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3115 | 0.200 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3238 | 0.200 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2004 | 639 | 0.190 |
Why?
|
| Analgesia, Patient-Controlled | 2 | 2013 | 117 | 0.190 |
Why?
|
| Hydroxyurea | 1 | 2003 | 284 | 0.190 |
Why?
|
| Urea Cycle Disorders, Inborn | 1 | 2021 | 32 | 0.190 |
Why?
|
| Pain | 6 | 2023 | 5100 | 0.190 |
Why?
|
| Mass Casualty Incidents | 1 | 2024 | 179 | 0.190 |
Why?
|
| Computer Systems | 1 | 2003 | 469 | 0.190 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2022 | 325 | 0.180 |
Why?
|
| Terbutaline | 1 | 2000 | 26 | 0.180 |
Why?
|
| National Institute of Child Health and Human Development (U.S.) | 1 | 2020 | 25 | 0.180 |
Why?
|
| Pandemics | 1 | 2020 | 8748 | 0.170 |
Why?
|
| Emergency Medical Services | 2 | 2014 | 1947 | 0.160 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2021 | 292 | 0.160 |
Why?
|
| Emergency Medicine | 3 | 2024 | 1222 | 0.160 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2000 | 347 | 0.160 |
Why?
|
| Vasodilator Agents | 1 | 2003 | 990 | 0.150 |
Why?
|
| Transportation of Patients | 2 | 2011 | 177 | 0.150 |
Why?
|
| Relief Work | 2 | 2011 | 131 | 0.140 |
Why?
|
| Nitric Oxide | 2 | 2004 | 2146 | 0.140 |
Why?
|
| Invertebrate Hormones | 1 | 1996 | 24 | 0.140 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2019 | 997 | 0.140 |
Why?
|
| Medical Records Systems, Computerized | 2 | 2013 | 1196 | 0.130 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 8052 | 0.130 |
Why?
|
| Escherichia coli Infections | 2 | 1996 | 524 | 0.120 |
Why?
|
| Emergency Service, Hospital | 4 | 2023 | 7939 | 0.120 |
Why?
|
| Internship and Residency | 3 | 2024 | 5952 | 0.110 |
Why?
|
| Safety | 2 | 2011 | 1159 | 0.110 |
Why?
|
| Research | 2 | 2020 | 1979 | 0.100 |
Why?
|
| Vascular Diseases | 2 | 2019 | 1162 | 0.100 |
Why?
|
| Hospitals, Public | 1 | 2014 | 204 | 0.100 |
Why?
|
| Patient Selection | 2 | 2012 | 4258 | 0.100 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2012 | 99 | 0.100 |
Why?
|
| Hemoglobin SC Disease | 1 | 2011 | 23 | 0.100 |
Why?
|
| Southwestern United States | 1 | 2011 | 39 | 0.100 |
Why?
|
| Blood Group Incompatibility | 1 | 2012 | 134 | 0.090 |
Why?
|
| Southeastern United States | 1 | 2011 | 93 | 0.090 |
Why?
|
| Child | 13 | 2024 | 80906 | 0.090 |
Why?
|
| Security Measures | 1 | 2011 | 83 | 0.090 |
Why?
|
| Blood Group Antigens | 1 | 2012 | 183 | 0.090 |
Why?
|
| Educational Measurement | 2 | 2019 | 1260 | 0.090 |
Why?
|
| Analgesics, Opioid | 3 | 2023 | 3837 | 0.080 |
Why?
|
| Serum Amyloid A Protein | 2 | 2000 | 128 | 0.080 |
Why?
|
| Anti-Infective Agents | 1 | 1996 | 983 | 0.080 |
Why?
|
| Isoantibodies | 1 | 2012 | 681 | 0.080 |
Why?
|
| Erythrocyte Transfusion | 1 | 2012 | 575 | 0.070 |
Why?
|
| Heart | 1 | 2000 | 4444 | 0.070 |
Why?
|
| Apolipoproteins | 2 | 2000 | 328 | 0.070 |
Why?
|
| United States Government Agencies | 1 | 2006 | 26 | 0.070 |
Why?
|
| Louisiana | 1 | 2006 | 104 | 0.070 |
Why?
|
| Troponin | 2 | 2000 | 536 | 0.060 |
Why?
|
| United States | 7 | 2024 | 73027 | 0.060 |
Why?
|
| Sepsis | 2 | 1996 | 2608 | 0.060 |
Why?
|
| Needs Assessment | 1 | 2011 | 1141 | 0.060 |
Why?
|
| Angina, Unstable | 2 | 2000 | 893 | 0.060 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2013 | 1085 | 0.050 |
Why?
|
| Data Collection | 1 | 2013 | 3326 | 0.050 |
Why?
|
| Counseling | 1 | 2011 | 1554 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2009 | 1443 | 0.050 |
Why?
|
| Point-of-Care Systems | 1 | 2011 | 1238 | 0.050 |
Why?
|
| Humans | 26 | 2024 | 767991 | 0.050 |
Why?
|
| Early Termination of Clinical Trials | 2 | 2012 | 70 | 0.050 |
Why?
|
| Leishmania infantum | 1 | 2001 | 17 | 0.050 |
Why?
|
| Pilot Projects | 3 | 2008 | 8740 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2011 | 2227 | 0.050 |
Why?
|
| Opsonin Proteins | 1 | 2001 | 144 | 0.050 |
Why?
|
| Mannans | 1 | 2001 | 58 | 0.050 |
Why?
|
| Clinical Competence | 3 | 2019 | 4857 | 0.050 |
Why?
|
| Asthma | 1 | 2000 | 6273 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2004 | 794 | 0.050 |
Why?
|
| Leishmaniasis, Visceral | 1 | 2001 | 100 | 0.040 |
Why?
|
| Fetal Hemoglobin | 1 | 2003 | 346 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2004 | 696 | 0.040 |
Why?
|
| Administration, Inhalation | 1 | 2003 | 1169 | 0.040 |
Why?
|
| Fentanyl | 1 | 2023 | 451 | 0.040 |
Why?
|
| Lectins | 1 | 2001 | 490 | 0.040 |
Why?
|
| Triage | 1 | 2006 | 996 | 0.040 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 1998 | 91 | 0.040 |
Why?
|
| Pain Measurement | 2 | 2013 | 3583 | 0.040 |
Why?
|
| Creatine Kinase | 1 | 2000 | 684 | 0.040 |
Why?
|
| Creatine | 1 | 2000 | 427 | 0.040 |
Why?
|
| Curriculum | 2 | 2024 | 3782 | 0.040 |
Why?
|
| Laboratories | 1 | 2021 | 463 | 0.040 |
Why?
|
| Health Personnel | 1 | 2011 | 3385 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2013 | 10396 | 0.030 |
Why?
|
| Rwanda | 1 | 2019 | 671 | 0.030 |
Why?
|
| Carrier Proteins | 2 | 2001 | 4937 | 0.030 |
Why?
|
| C-Reactive Protein | 2 | 1998 | 3858 | 0.030 |
Why?
|
| Education, Medical, Graduate | 2 | 2008 | 2420 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2004 | 1671 | 0.030 |
Why?
|
| Protein Precursors | 1 | 2000 | 1134 | 0.030 |
Why?
|
| Isoenzymes | 1 | 2000 | 1688 | 0.030 |
Why?
|
| Random Allocation | 2 | 1996 | 2396 | 0.030 |
Why?
|
| United Arab Emirates | 1 | 2014 | 42 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2008 | 6283 | 0.030 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 1996 | 352 | 0.030 |
Why?
|
| Endotoxins | 1 | 1996 | 519 | 0.030 |
Why?
|
| Adolescent | 8 | 2019 | 89155 | 0.030 |
Why?
|
| Peritonitis | 1 | 1995 | 368 | 0.030 |
Why?
|
| Prospective Studies | 5 | 2003 | 54924 | 0.030 |
Why?
|
| Health Resources | 1 | 2019 | 950 | 0.030 |
Why?
|
| Male | 13 | 2023 | 364641 | 0.030 |
Why?
|
| Acute Chest Syndrome | 1 | 2012 | 32 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 1996 | 1888 | 0.020 |
Why?
|
| Child, Preschool | 4 | 2019 | 42665 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 7445 | 0.020 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 1994 | 506 | 0.020 |
Why?
|
| Hydromorphone | 1 | 2011 | 70 | 0.020 |
Why?
|
| Female | 13 | 2023 | 397113 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2023 | 3476 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2021 | 9666 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2003 | 12464 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2001 | 4351 | 0.020 |
Why?
|
| Adult | 9 | 2019 | 223583 | 0.020 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 1994 | 1105 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 1736 | 0.020 |
Why?
|
| Morphine | 1 | 2011 | 658 | 0.020 |
Why?
|
| Survival Rate | 2 | 2000 | 12828 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2012 | 2433 | 0.020 |
Why?
|
| Foreign Medical Graduates | 1 | 2005 | 76 | 0.010 |
Why?
|
| Amniotic Fluid | 1 | 1985 | 381 | 0.010 |
Why?
|
| Learning | 1 | 2013 | 1759 | 0.010 |
Why?
|
| Resource Allocation | 1 | 2005 | 354 | 0.010 |
Why?
|
| Collectins | 1 | 2001 | 18 | 0.010 |
Why?
|
| Observer Variation | 1 | 2008 | 2618 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 26375 | 0.010 |
Why?
|
| Australia | 1 | 2005 | 1265 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2012 | 5314 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2009 | 65364 | 0.010 |
Why?
|
| Rats | 1 | 1996 | 23751 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 1996 | 18344 | 0.010 |
Why?
|
| Canada | 1 | 2005 | 2129 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 10757 | 0.010 |
Why?
|
| Amino Acids | 1 | 1985 | 1716 | 0.010 |
Why?
|
| Sensitivity and Specificity | 2 | 2008 | 14718 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1995 | 9252 | 0.010 |
Why?
|
| Mannose-Binding Lectins | 1 | 1998 | 101 | 0.010 |
Why?
|
| Immune Sera | 1 | 1998 | 605 | 0.010 |
Why?
|
| Logistic Models | 1 | 2013 | 13289 | 0.010 |
Why?
|
| Length of Stay | 1 | 2011 | 6495 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2019 | 81746 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 1998 | 11519 | 0.010 |
Why?
|
| Research Design | 1 | 2013 | 6211 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1994 | 6371 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1998 | 1625 | 0.010 |
Why?
|
| Fellowships and Scholarships | 1 | 2005 | 1135 | 0.010 |
Why?
|
| Prevalence | 1 | 2012 | 15867 | 0.010 |
Why?
|
| Young Adult | 2 | 2012 | 60048 | 0.010 |
Why?
|
| Reference Standards | 1 | 1998 | 1013 | 0.010 |
Why?
|
| Age Factors | 1 | 2011 | 18407 | 0.010 |
Why?
|
| Middle Aged | 5 | 2012 | 223422 | 0.010 |
Why?
|
| Immunoassay | 1 | 1998 | 746 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2001 | 1793 | 0.010 |
Why?
|
| Bicarbonates | 1 | 1995 | 293 | 0.010 |
Why?
|
| G(M1) Ganglioside | 1 | 1994 | 87 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2001 | 6119 | 0.010 |
Why?
|
| Troponin T | 1 | 1998 | 787 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1994 | 915 | 0.010 |
Why?
|
| Animals | 4 | 2001 | 169222 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2014 | 24314 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1998 | 3813 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2001 | 3228 | 0.010 |
Why?
|
| Thrombolytic Therapy | 1 | 2000 | 2055 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1994 | 1353 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1995 | 1335 | 0.010 |
Why?
|
| Fibrinolytic Agents | 1 | 2000 | 2080 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1994 | 1863 | 0.010 |
Why?
|
| Rabbits | 1 | 1995 | 4771 | 0.000 |
Why?
|
| Electrocardiography | 1 | 2000 | 6411 | 0.000 |
Why?
|
| Aged | 2 | 2012 | 171446 | 0.000 |
Why?
|
| Case-Control Studies | 1 | 2001 | 22287 | 0.000 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 1985 | 267 | 0.000 |
Why?
|
| Survival Analysis | 1 | 1995 | 10098 | 0.000 |
Why?
|
| Pregnancy Trimester, Second | 1 | 1985 | 737 | 0.000 |
Why?
|
| Predictive Value of Tests | 1 | 1998 | 15442 | 0.000 |
Why?
|
| Reproducibility of Results | 1 | 1998 | 20218 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1995 | 8540 | 0.000 |
Why?
|
| Infant | 1 | 2001 | 36534 | 0.000 |
Why?
|
| Prognosis | 1 | 2000 | 29979 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1994 | 19017 | 0.000 |
Why?
|
| Reference Values | 1 | 1985 | 4938 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2001 | 59598 | 0.000 |
Why?
|
| Mice | 1 | 1994 | 82024 | 0.000 |
Why?
|
| Pregnancy | 1 | 1985 | 30260 | 0.000 |
Why?
|